Rough Medications as Anticancer Specialists

Abstract

Albeit enormous advance has been made in fundamental disease science and in the improvement of novel growth medicines, malignancy remains a main source of death on the planet. The etiopathogenesis of disease is mind boggling. Other than hereditary inclination, known ecological components connected with disease are: eating routine, way of life, and natural poisons. Danger of medications and inevitable backslide of diseases add to high malignancy demise rates. Current restorative mediations for malignancy surgery, chemotherapy, radiotherapy, thermotherapy, and so on are a long way from being remedial for some types of growth. Chemotherapy, specifically, however the most regularly utilized disease treatment, is generally connected with symptoms with shifting degrees of seriousness. The motivation behind this brief survey is to a mass current writing on some rough medications and to concentrate on their valuable parts and medication focuses in malignancy treatment and chemoprevention. In spite of the fact that their pharmacological systems and biochemical parts in disease science and tumor chemoprevention are not completely comprehended, unrefined medications are accepted to have nutriceutical impacts upon disease patients.

Keywords

Malignancy, Medications, Phytochemicals, Anticancer, Chemotherapy

Introduction of Crude Drugs

All through the historical backdrop of solution, numerous powerful medications were gotten from normal concentrates of plants or creatures. In the East since old times, particularly in China and Korea, individuals have been utilizing plant rhizomes, leaves or barks and other normal materials absorbed liquor or wine as medications to treat sickness [1-7]. These medications that originate from plants are called unrefined medications. Flagging the significance of medications from normal inceptions is the developing confirmation that shows that weight control plans rich in vegetables and organic products can diminish the danger of various perpetual maladies, counting growth, cardiovascular illnesses, diabetes, etc. [8-12].

In this way, as disease frequency is on the ascent, and growth treatment still needs viable medications without critical symptoms, the investigation of unrefined medications has turned out to be more essential. Luckily, sub-atomic science and biochemical innovation advancement has advanced research on rough medications [13-19]. New sanitization and investigation advancements have empowered rough medications to be produced and made accessible for far reaching use, and have made obvious progress in tumor treatment and malignancy science look into.

Rough medications may go about as medicines themselves, or their viable components might be utilized for tumor treatment straightforwardly or as supplemental applications in the facility [20-26]. Also, rough medications are utilized as a premise to screen for better hostile to growth sedate forerunners or in different ways that serve researchers in disease investigate as expert medications.

 Examples of Crude Drugs as Anticancer Agents

Helpful impacts of unrefined medications are accepted to be ascribed to plant phytochemicals (different considers plant sustenance’s, for example, carotenoids, antioxidative vitamins, phenolic mixes, terpenoids, steroids, indoles, and strands, and so forth [27-31]. These are the successful components considered to be in charge of lessening tumor hazard. Beneath we refer to a few cases of phytochemicals that are utilized or have the potential for use in malignancy treatment.

Curcumin

Curcumin, utilized as a part of Chinese solution and in the Indian customary sustenance of curry as the yellow shading specialist in turmeric, is known for its cancer prevention agent, calming, antiviral, antibacterial, antifungal, and anticancer exercises and possibly battle different issue including diabetes, sensitivities, joint pain, and Alzheimer's sickness. Another anticancer impact of curcumin was seen in an unpublished Phase II learn at MD Anderson Cancer Center in which 25 pancreatic growth patients were observed while taking curcumin and no other treatment [32-37].

Carotenoids

Like curcumin, carotenoids, found in almost all brilliantly shaded products of the soil on the other hand fish, have solid growth battling properties. Their anticancer impact originates from their cancer prevention agent properties. Cancer prevention agents shield cells from free radicals, substances that work to crush cell layers and DNA. As cancer prevention agents, carotenoids have numerous advantages [38-42]. For instance, smokers have a tendency to have higher groupings of free radicals in their blood because of the chemicals they breathe in.

Astaxanthin is another carotenoid, found in salmon, red fish, shrimp and crab, which demonstrates against cancer-causing impacts in mouse lung and liver disease models [43-46]. In the HepG2 human liver malignancy cell line, astaxanthin altogether restrained, in a measurements subordinate way, the expansion of liver tumor cells.

Stream cytometric examination exhibited that astaxanthin controlled the cell cycle movement at G1 and instigated apoptosis. Facilitate examinations through constant quantitative RT-PCR uncovered that astaxanthin improved the statement of p21CIP1/WAF1, GADD153 and c-myc qualities, recommending that astaxanthin will be a promising specialist for use in chemoprevention or as a tumor remedial [47-51].

Polysaccharide

Oranges not just contain the carotenoid β-carotene that is in charge of their orange shading, additionally contain another anticancer operator, GCS-100, a polysaccharide got from citrus pectin [52-55]. In different myeloma cells, GCS-100 overcomes bortezomib resistance and upgrades dexamethasone-incited apoptosis. At the end of the day, even within the sight of bone marrow–derived stromal cells (BMSCs), GCS-100 represses the development of numerous myeloma cells and even pieces VEGF-initiated relocation of the cells, recommending hostile to angiogenic action [56-60].

Mushrooms

Another natural ingredient with potential as a crude drug, given its anti-tumor as well as antiviral, and antibacterial properties, is the mush room. The effects of mushrooms are thought to be due to their ability to modulate immune cell functions [61-64]. These compounds from macromycetes fungi belong mainly to polysaccharides especially beta-dglucan derivates, glycopeptide/protein complexes (polysaccharide-peptide/protein complexes), proteoglycans, proteins, and triterpenoids [65-70].

Another normal fixing with potential as a rough medication, given its hostile to tumor and also antiviral, and antibacterial properties, is the mush room. The impacts of mushrooms are thought to be because of their capacity to regulate insusceptible cell capacities [71-73]. These mixes from macromycetes growths have a place for the most part with polysaccharides particularly beta-dglucan derivate, glycopeptide/protein edifices (polysaccharide-peptide/protein buildings), proteoglycans, proteins, and triterpenoids.

Among polysaccharides, beta (1- - >3)- d-glucans and their peptide/protein derivates, and different proteins-contagious immunomodulatory proteins (Fips) have a critical part in immunomodulating what's more, against tumor exercises [74-75].

Resveratrol

Another conceivable unrefined medication or rough medication component found in the skin of red grapes and, along these lines, in red wine that has been recognized on the premise of its capacity to restrain cyclooxygenase (COX) movement is resveratrol.

Resveratrol hinders cell occasions connected with tumor start, advancement, and movement. Assist, it smothers TNF-α-actuated initiation of atomic translation components NF-B, activator protein-1 (AP-1) and apoptosis, proposing a potential part in lessening oxidative stretch and lipid peroxidation [76].

Green tea

Like resveratrol in the skin of grapes, green tea is now well-known to most people for having medicinal benefit. Green tea polyphenol- (-)- epigallocatechin-3-gallate (EGCG) has various beneficial properties including chemo preventive, anti-carcinogenic, and antioxidant actions [77,78]. Like resveratrol in the skin of grapes, green tea is presently outstanding to the vast majority for having restorative advantage. Green tea polyphenol-(-)- epigallocatechin-3-gallate (EGCG) has different useful properties including chemo preventive, anti-carcinogenic, and cancer prevention agent activities.

The characteristic elements of curcumin, carotenoids, mushrooms, EGCG in green tea, resveratrol in red grape skin, and GCS-100 in citrus pectin are just a portion of the characteristic fixings that can, as paclitaxel (Taxol), get to be unrefined medications with potential multi-focusing on adequacy in battling disease.

Herbals

Scutellaria baicalensis is a broadly utilized Chinese home grown pharmaceutical generally utilized as mitigating and anticancer treatment that is being tried as a treatment for prostate growth. Two human prostate malignancy cell lines (LNCaP, androgen ward, and PC-3, androgen free) were evaluated for development restraint when presented to S. baicalensis, applied measurements and time-subordinate expanded development hindrance in both cell lines.

After treatment with S. baicalensis, PGE2 amalgamation in both cells was altogether decreased, coming about from direct hindrance of COX-2 movement instead of COX-2 protein concealment [79-84]. S. baicalensis additionally hindered prostate-particular antigen creation in LNCaP cells.

At long last, S. baicalensis smothered articulation of cyclin D1 in LNCaP cells, bringing about a G1 stage capture, while restraining cdk1 expression and kinase action in PC-3 cells, eventually prompting to a G2/M cell cycle capture.

Artemisia asiatica has likewise been regularly utilized as a part of conventional Asian medication for the treatment of sicknesses including aggravation, malignancy, and microbial disease [85-89]. A concentrate of A. asiatica, DA-9601, with ethanol, blocked TNF-α-intervened provocative flags by possibly regulating the p38 kinase pathway or potentially a flag prompting to NF-  B-subordinate pathways in gastric epithelial cells.

Isoliquiritigenin is a characteristic flavonoid secluded from licorice, shallot and bean grows that has essentially repressed, in a measurements and time dependent way, the expansion of disease cells in the A549 human lung malignancy cell line [90-95]. Stream cytometric examination exhibited that isoliquiritigenin limited the cell cycle progressionat G2/M stage.

A sharp element of hot bean stew peppers-capsaicin (8-methyl-N-vanillyl-6-nonenamide), has been accounted for to have significant anti-carcinogenic and hostile to mutagenic exercises [96-100]; it can actuate apoptosis in exceptionally metastatic B16-F10 murine melanoma cells and, in a focus subordinate way, restrain their development.

Conclusion

The above passages demonstrate a delegate test of promising regular components, including Paclitaxel (Taxol), curcumin, β-carotene, astaxanthin, citrus pectin, mushroom, resveratrol, EGCG, Scutellaria baicalensis, Artemisia asiatica, red and white ginseng separates, isoliquiritigenin, furthermore, capsaicin, that are being utilized and tried as rough medications or components of unrefined medications in research and in the facility.

Rough medications are not new. To date, unrefined medications have shown an essential part in the improvement of new anticancer medications. Be that as it may, assessment of rough medications up to this point has been barely centered on the plants and fish.

Eastern prescription has a long convention of utilizing logical strategies including normal dynamic constituents as precursor mixes and after that through natural union and basic change finding new medications or joining common mixes with restorative impact.

Unrefined medications or their dynamic fixings may have various systems of activity. By expanding research into rough medications, we would like to distinguish the most encouraging operators and get it their numerous activities. At last we would like to tap the endless capability of this class of operators and enhance malignancy treatment.

References

1. Kohn EC, et al. Dose-intense taxol: high response rate in patients with platinum-resistant recurrent ovarian cancer. J Natl Cancer Inst. 1994;86:18-24.
2. Morgan MA, et al. Paclitaxel poliglumex and carboplatin as first-line therapy in ovarian, peritoneal or fallopian tube cancer: a phase I and feasibility trial of the Gynecologic Oncology Group. GynecolOncol. 2008;110:329-335.
3. Mou X. Cancer prevention by astaxanthin, a natural carotenoid. J Kyoto Prefectural Univer Med. 2005;114:21-29.
4. Duan Z, et al. CDDO-Me, a synthetic triterpenoid, inhibits expression of IL-6 and Stat3 phosphorylation in multi-drug resistant ovarian cancer cells. Cancer ChemotherPharmacol. 2009;63:681-689.
5. Gardner ER, et al. Randomized crossover pharmacokinetic study of solvent-based paclitaxel and nab-paclitaxel. Clin Cancer Res. 2008;14:4200-4205.
6. Rossi D, et al. Neoadjuvant chemotherapy with low dose of pegylated liposomal doxorubicin plus weekly paclitaxel in operable and locally advanced breast cancer. Anticanc Drugs. 2008;19:733-737.
7. Ettinger DS, et al. Phase II study of paclitaxel in patients with extensive-disease small-cell lung cancer: an Eastern Cooperative Oncology Group study. J ClinOncol. 1995;13:1430-1435.
8. Iranzo V, et al. Induction chemotherapy followed by concurrent chemoradiation for patients with non-operable stage III non -small-cell lung cancer. Lung Can. 2009;63:63-67.
9. Pennathur A, et al. Long-term results of a phase II trial of neoadjuvant chemotherapy followed by esophagectomy for locally advanced esophageal neoplasm. Ann Thorac Surg. 2008;85:1930-1936.
10. Okano J, et al. The growth inhibition of liver cancer cells by paclitaxel and the involvement of extracellular signal-regulated kinase and apoptosis. Oncol Rep. 2007;17:1195-1200.
11. Parness J and Horwitz SB. Taxol binds to polymerized tubulin in vitro. J Cell Biol. 1981;91:479 -487.
12. Andreu JM, et al. Low resolution structure of microtubules in solution. Synchrotron X-ray scattering and electron microscopy of taxolinduced microtubules assembled from purified tubulin in comparison with glycerol and MAPinduced microtubules. J Mol Biol. 1992;226:169-184.
13. Schiff PB and Horwitz SB. Taxolstabilizes microtubules in mouse fibroblast cells. ProcNatlAcad Sci. 1980;77:1561-1565.
14. Kunnumakkara AB, et al. Curcumin inhibits proliferation, invasion, angiogenesis and metastasis of different cancers through interaction with multiple cell signaling proteins. Cancer Lett. 2008;269:199-225.
15. Steward WP and Gescher AJ. Curcumin in cancer management: recent results of analogue design and clinical studies and desirable future research. MolNutr Food Res. 2008;52:1005-1009.
16. Kamat AM,et al. Curcumin potentiates the apoptotic effects of chemotherapeutic agents and cytokines through down -regulation of nuclear factor-kappaB and nuclear factor-kappaB-regulated gene products in IFN-alpha-sensitive and IFN-alpha-resistant human bladder cancer cells. Mol Cancer Ther. 2007;6:1022-1030.
17. Kunnumakkara AB, et al. Curcumin potentiates antitumor activity of gemcitabine in an orthotopic model of pancreatic cancer through suppression of proliferation, angiogenesis, and inhibition of nuclear factorkappaB-regulated gene products. Cancer Res. 2007;67:3853-3861.
18. Aggarwal BB, et al. Curcumin suppresses the paclitaxel-induced nuclear factor-kappaB pathway in breast cancer cells and inhibits lung metastasis of human breast cancer in nude mice. Clin Cancer Res. 2005;11:7490-7498.
19. Liu Y, et al. Synergistic effects of curcumin on alltrans retinoic acid- and 1 alpha,25- dihydroxyvitamin D3-induced differentiation in human promyelocytic leukemia HL-60 cells. Oncol Res. 1997;9:19-29.
20. Carter A. Curry compound fights cancer in the clinic. J Natl Cancer Inst. 2008;100:616-617.
21. Johnson JJ and Mukhtar H. Curcumin for chemoprevention of colon cancer. Cancer Lett. 2007;255:170-181.
22. Cruz-Correa M, et al. Combination treatment with curcumin and quercetin of adenomas in familial adenomatous polyposis. ClinGastroenterolHepatol. 2006;4:1035-1038.
23. Chadalapaka G, et al. Curcumin decreases specificity protein expression in bladder cancer cells. Cancer Res. 2008;68:5345-5354.
24. Narasimhan M and Ammanamanchi S. Curcumin blocks RON tyrosine kinase-mediated invasion of breast carcinoma cells. Cancer Res. 2008;68:5185-5192.
25. Surh YJ and Chun KS. Cancer chemopreventive effects of curcumin. AdvExp Med Biol. 2007;595:149-172.
26. Ruano-Ravina A, et al. Diet and lung cancer: a new approach. Eur J Cancer Prev. 2000;9:395-400.
27. Zhang S, et al. Dietary carotenoids and vitamins A, C, and E and risk of breast cancer. J Natl Cancer Inst. 1999;91:547-556.
28. Cook NR, et al. Betacarotene supplementation for patients with low baseline levels and decreased risks of total and prostate carcinoma. Cancer. 1999;86:1783-1792.
29. Chlon TM, et al. Retinoids modulate expression of the endocytic partners megalin, cubilin, and disabled-2 and uptake of vitamin D-binding protein in human mammary cells. J Nutr. 2008;138:1323-1328.
30. Schug TT, et al. Overcoming retinoic acidresistance of mammary carcinomas by diverting retinoic acid from PPARbeta/delta to RAR. ProcNatlAcad Sci. 2008;105:7546- 7551.
31. Czeczuga-Semeniuk E, et al. Can vitamin A modify the activity of docetaxel in MCF-7 breast cancer cells? Folia HistochemCytobiol. 2007;45Suppl 1: S169-174.
32. Dragan S, et al. Role of multi-component functional foods in the complex treatment of patients with advanced breast cancer. Rev Med ChirSoc Med Nat Iasi. 2007;111:877-884.
33. Young CY, et al. Carotenoids and prostate cancer risk. Mini Rev Med Chem. 2008;8:529-537.
34. Ahn J, et al. Family history of prostate cancer and prostate cancer risk in the Alpha-Tocopherol, Beta-Carotene Cancer Prevention (ATBC) Study. Int J Cancer. 2008;123:1154-1159.
35. Dahan K, et al. Lycopene in the prevention of prostate cancer. J SocIntegrOncol. 2008;6:29-36.
36. Lens M and Medenica L. Systemic retinoids in chemoprevention of non-melanoma skin cancer. Expert OpinPharmacother. 2008;9:1363-1374.
37. Pelucchi C, et al. Dietary intake of carotenoids and retinol and endometrial cancer risk in an Italian case-control study. CancCaus Cont. 2008;19:1209-1215.
38. Sarangi I, et al. Anti-tumor and immunomodulatingeffects of Pleurotusostreatus mycelia-derived proteoglycans. IntImmunopharmacol. 2006;6:1287-1297.
39. Kodama N, et al. Effect of Maitake (Grifolafrondosa) D-Fraction on the activation of NK cells in cancer patients. J Med Food 2003;6:371-377.
40. Wu D, et al. Dietary supplementation with white button mushroom enhances natural killer cell activity in C57BL/6 mice. J Nutr. 2007;137:1472-1477.
41. Moradali MF, et al. Immunomodulating and anticancer agents in the realm of macromycetes fungi (macrofungi). IntImmunopharmacol. 2007;7:701-724.
42. Kim JY, et al. Immunostimulatory activities of polysaccharides from liquid culture of pinemushroomTricholomamatsutake. J MicrobiolBiotechnol. 2008;18:95-103.
43. Jang M, et al. Cancer chemopreventive activity of resveratrol, a natural product derived from grapes. Science. 1997;275:218-220.
44. Manna SK, et al. Resveratrol suppresses TNF-induced activation of nuclear transcription factors NF-kappa B, activator protein-1, and apoptosis: potential role of reactive oxygen intermediates and lipid peroxidation. J Immunol. 2000;164:6509-6519.
45. Adhami VM, et al. Suppression of ultraviolet B exposure-mediated activation of NF-kappaB in normal human keratinocytes by resveratrol. Neoplasia. 2003;5:74-82.
46. Khan N and Mukhtar H. Multitargeted therapy of cancer by green tea polyphenols. Cancer Lett. 2008;269:269-280.
47. Richmond A. Nf-kappa B, chemokine gene transcription and tumour growth. Nat Rev Immunol. 2002;2:664-674.
48. Ye F, et al. Molecular mechanism of anti-prostate cancer activity of Scutellariabaicalensis extract. Nutr Cancer. 2007;57:100-110.
49. Wheeler DS, et al. Epigallocatechin-3- gallate, a green tea-derived polyphenol, inhibits IL-1 beta-dependent proinflammatory signal transduction in cultured respiratory epithelial cells. J Nutr. 2004;134:1039-1044.
50. Jun HS, et al. Capsaicin induced apoptosis of B16-F10 melanoma cells through down-regulation of Bcl-2. Food ChemToxicol. 2007;45:708-715.
51. Siqueira EP, et al. ChamaeCostussubsessilis and ChamaeCostuscuspidatus (Nees& Mart) C.Specht and D.W.Stev as Potential Sources of Anticancer Agents. Nat Prod Chem Res.2016;4:204.
52. Nadeem F, et al. Red Sea Microbial Diversity for Antimicrobial and Anticancer Agents. J MolBiomarkDiagn. 2015;7:267.
53. Noro J, et al. Evaluation of New Naphthalimides as Potential Anticancer Agents against Breast Cancer MCF-7, Pancreatic Cancer BxPC-3 and Colon Cancer HCT-15 Cell Lines. Organic ChemCurr Res. 2015;4:144.
54. Saganuwan SA and Ndakotsu AM. Standardization and Scoring of the Body Surface Area (BSA) Formulas for Calculation of the Doses of Anticancer Agents for Cancer Patients from the North-Western Nigeria. J Cancer SciTher.2015;7:012-018.
55. Matsubara MM, et al. Depletion of RUVBL2 in Human Cells Confers Moderate Sensitivity to Anticancer Agents. J Cancer SciTher. 2014;6:440-445.
56. Venugopal DVR, et al. Synthesis, of Novel Piperine Analogs of DipeptidylBoronic Acid as Antimicrobial and Anticancer Agents. Med chem.2014;4:606-610.
57. Zainal B, et al. Anticancer Agents from Non-Edible Parts of Theobroma cacao. Nat Prod Chem Res. 2014;2:134.
58. Han DW. Advances of Green Tea Catechins towards Smart Anticancer Agents. BiochemPharmacol. 2014;3:e153.
59. Abd-Elsalam KA and Hashim AF. Hidden Fungi as Microbial and Nano- Factories for Anticancer Agents. Fungal Genom Biol. 2013;3:e115.
60. Qin X, et al. Synthesis, Molecular Modeling and Biological Evaluation of 7-Sulfanylflavone as Anticancer Agents. Medchem. 2011;1:017-020.
61. Heidari A. A Chemotherapeutic and Biospectroscopic Investigation of the Interaction of Double–Standard DNA/RNA–Binding Molecules with Cadmium Oxide (CdO) and Rhodium (III) Oxide (Rh2O3) Nanoparticles as Anti–Cancer Drugs for Cancer Cells’ Treatment. Chemo Open Access.2016;5:e129.
62. Punganuru SR, et al. Colchicine-Based Hybrid Anticancer Drugs to Combat Tumor Heterogeneity. Med chem (Los Angeles). 2016;6:165-173.
63. Bhandari M, et al. Traditional Ayurvedic medicines: Pathway to develop anti-cancer drugs. J Mol Pharm Org Process Res. 2015;3:130.
64. Liu JJ, et al. Systems Pharmacology for the Study of Anticancer Drugs: Promises and Challenges. ClinPharmacolBiopharm. 2015;4:140.
65. Chauhan A and Tyagi R. Herbal Anti-Cancer Drugs: A Better Way to Cure the Disease. Pharm Anal Acta. 2015;6:e176.
66. Adcock AF, et al. Three- Dimensional (3D) Cell Cultures in Cell-based Assays for in-vitro Evaluation of Anticancer Drugs. J Anal Bioanal Tech. 2015;6:247.
67. Agrawal P. Recent Advances in Anticancer Drugs Development: G-Quadruplex as New Drug Target. J Pharmacovigilance.2015;3:e134. 
68. Ananthula S. Bioavailability and Bioequivalence Issues Associated With Oral Anticancer Drugs and Effect on Drug Market. J BioequivAvailab.2014;6:e56.
69. Xiong K. Call for New Approaches for Subcellular Delivery of Anticancer Drugs. J Biomol Res Ther.2014;3:e138.
70. Sultana N, et al. Simultaneous Liquid Chromatographic Determination of Two Co-Prescribed Anti- Cancer Drugs in Bulk Drug, Dosage Formulations and in Human Serum Using Multivariate Technique: Application to in vitro Drug Interaction. Pharmaceut Anal Acta. 2013;4:215. 
71. González-Sabin J and Morís F. Exploring Novel Opportunities for Aureolic Acids as Anticancer Drugs. BiochemPharmacol. 2013;2:e140. 
72. Schmitt S and Dou QP. Metal-Based Compounds as Proteasome-Inhibitory Anti-Cancer Drugs. J Pharmacovigilance.2013;1:e101. 
73. Casacó A, et al. Anti- Epidermal Growth Factor/Epidermal Growth Factor Receptor Therapeutic Anticancer Drugs and the Wound Healing Process. J Cancer SciTher.2012;4:324-329.
74. Zhang J and Zhou SF. Can We Discover “Really Safe and Effective” Anticancer Drugs? AdvPharmacoepidem Drug Safety. 2012;1:e113. 
75. Grillier-Vuissoz I, et al. PPAR?-independent Activity of Thiazolidinediones: A Promising Mechanism of Action for New Anticancer Drugs? J CarcinogeneMutagene.2012;S8:002.
76. Hiwasa T, et al. Functional Similarity of Anticancer Drugs by MTT Bioassay. J Cancer SciTher. 2011;3:250-255.
77. Skopec R. Integrin Inhibitor Drugs: New Therapy Against Metastasis. J MolBiomarkDiagn.2016;7:298. 
78. Hawkins F and Jimenez FE. Effect of Adherence in Osteorporosis Treatment Drugs. J OsteoporPhys Act.2016;4:e114. 
79. Landefeld K, et al. Hypertensive Crisis: The Causative Effects of Nonsteroidal Anti-Inflammatory Drugs. J Clin Case Rep. 2016;6:838.
80. Zhao XY, et al. Redeveloping Drugs Based on Existing Patents. Primary Health Care. 2016;6:233.
81. Batisse Anne. "Sex and Drugs" in Substance-Using Men Who Have Sex with Men in France. AdvPharmacoepidemiol Drug Saf.2016;5:209. 
82. Parisotto M, et al. Risk-Benefit Profile of Novel Anti-diabetic Drugs: Current Perspectives. J Pharmacovigil. 2016;4:e160.
83. Mondon K, et al. Influence of the Macro- and/or Microstructure of Cross-Linked Hyaluronic Acid Hydrogels on the Release of Two Model Drugs. J Glycobiol. 2016;5:119.
84. Seeman MV. Exercise and Antipsychotic Drugs. J Pat Care.2016;2:114.
85. Dasari H, et al. Concomitant Use of Neuroprotective Drugs in Neuro Rehabilitation of Multiple Sclerosis. Int J Phys Med Rehabil. 2016;4:348.
86. Lu DY, et al. Discover Natural Chemical Drugs in Modern Medicines. Metabol. 2016;6:181.
87. Alaqad K and Saleh TA. Gold and Silver Nanoparticles: Synthesis Methods, Characterization Routes and Applications towards Drugs. J Environ Anal Toxicol. 2016;6:384. 
88. Dudhipala N, et al. Recent Updates in the Formulation Strategies to Enhance the Bioavailability of Drugs Administered via Intranasal Route. J BioequivAvailab. 2016;8:204-207.
89. Yuldasheva GA, et al. The Mechanism of Anti-Cancer Activity of Complexes of Molecular Iodine with α-Dextrins and Polypeptides and Lithium Halogenides. J AntivirAntiretrovir. 2016;8:072-078.
90. Kalayci S. Antimicrobial Properties of Various Non-Antibiotic Drugs against Microorganisms. J Bioanal Biomed. 2016;8:e142. 
91. Ceron-Carrasco JP, et al. Application of Computational Drug Discovery Techniques for Designing New Drugs against Zika Virus. Drug Des. 2016;5:e131.
92. Sarkar S, et al. Current Overview of Anti-Tuberculosis Drugs: Metabolism and Toxicities. Mycobact Dis. 2016;6:209.
93. Bhattacharjee J. Mass Drugs Administration in India - A Failure Story. Epidemiology. 2016;6:252. 
94. Canan KUS. Novel Antipsychotic Drugs Approved in 2015: Brexpiprazole, Cariprazine, AripiprazoleLauroxil. Med chem. 2016;6:425-428.
95. Lee PYF and Brock J. Intra-articular Injections for Osteoarthritis: From Bench to Bedside, can we Teach Old Drugs New Tricks?. J Arthritis. 2016;5:e111.
96. Gopi S, et al. Introduction of Nanotechnology in Herbal Drugs and Nutraceutical: A Review. J NanomedineBiotherapeuticDiscov. 2016;6:143.
97. Biondi F, et al. Serious Adverse Reactions Caused by Counterfeit Drugs. A Clinical Case of Transient Global Amnesia Caused by Dietary Supplement Containing a High Dose of Sildenafil. J Pharmacovigil. 2016;4:212. 
98. Martin A. Aspects of Substance Displacement - From Illicit Drugs to Novel Psychoactive Substances. J Addict Res Ther. 2016;7:283. 
99. Polo F and Toffoli G. Point-of-Care for Therapeutic Drug Monitoring of Antineoplastic Drugs. Med chem. 2016;6:e108. 
100. Beyene T, et al. Assessment of Rational Veterinary Drugs Use in Livestock at Adama District Veterinary Clinic, Central Ethiopia. J VeterinarSci Techno. 2016;7:319.